New drug combo aims to stop dangerous transplant complication in kids
NCT ID NCT06128070
Summary
This study tests whether adding the drug ruxolitinib to two standard medications can better prevent graft-versus-host disease (GVHD) in children and young adults receiving bone marrow transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body, and preventing it is crucial for transplant success. The trial will enroll 40 patients aged 2-22 to evaluate safety and effectiveness over two years of follow-up.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.